Synthetic DHEA derivative / NGF mimetic

Plain-language summaryIntrigue 70 / 100

BNN-27 is a synthetic neurosteroid derivative of DHEA developed at the BRFAA in Athens. It mimics nerve growth factor (NGF) without activating other DHEA pathways. Investigated for neurodegeneration. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

53/100

Selective TrkA agonist with a genuinely novel scaffold; single-lab evidence limits confidence

BNN-27 is one of the more conceptually elegant compounds we’ve come across in the neurotrophin space. The Gravanis group at the University of Crete has been quietly building a case for a class they call micronutrotropins: small steroid-derived molecules that can engage TrkA, the high-affinity NGF receptor, without triggering p75NTR. That distinction matters more than it might look at first glance. p75NTR is the “dark side” receptor in neurotrophin biology. Under conditions where TrkA is absent or outcompeted, p75NTR can drive apoptosis rather than survival signaling. Separating those two pharmacologically is a genuinely useful thing to do, and not many compounds come close.

What we like here is the scaffold decision. BNN-27 sits on a modified DHEA backbone with a spiroepoxy-thiazoline substituent at C17. It’s a real small molecule, orally bioavailable by rodent data, and CNS-penetrant by inference from the steroid core. That matters because NGF itself is a 26kDa protein with essentially no practical pharmacokinetic profile for CNS applications. Getting TrkA activation from something you can put in a gavage tube, or theoretically formulate for systemic delivery, is the entire pharmacological problem the compound is designed to solve.

The evidence base is where we have to be direct. This is basically a single-lab story. The Gravanis group and Bionature E.A. Ltd have published BNN-27 data in rodent models of diabetic peripheral neuropathy, retinal ganglion cell degeneration, and amyloid-related neurotoxicity. The preclinical results are consistently positive. But consistently positive rodent results from a single consortium are a yellow flag, not a green one. Independent replication has not materialized in any meaningful way, and the methodology is hard to assess from the outside when the compound and the publications come from the same source.

Theres also no clinical data. Not even a phase 1 safety readout. The compound has circulated in the preclinical literature for well over a decade without attracting the external interest needed to push it into human studies. That gap says something about how the broader field has weighted the evidence, even accounting for the capital-intensive nature of novel neurotrophin programs.

For bench researchers, though, BNN-27 has real probe value right now. If your program involves dissecting TrkA-specific survival signaling from p75NTR-mediated death pathways, this is probably your cleanest available small-molecule tool. The selectivity profile is well-characterized in Gravanis lab conditions, and the underlying mechanistic hypothesis is sound. We think investigators working on neurodegeneration models, retinal biology, or diabetic neuropathy should have this on the radar as a tool compound. Just dont treat it as a validated therapeutic lead until someone outside the originating lab replicates the signal.

Novelty: 65
Mechanism promise: 72
In-category differentiation: 60
Evidence quality: 25
Translational signal: 30
Research bench value: 55

Rationale BNN-27 earns its novelty and mechanism scores for the elegant separation of TrkA from p75NTR signaling via a small, orally bioavailable steroid scaffold, a genuinely underexplored pharmacological angle in neurotrophin biology; evidence quality and translational signal are dragged down hard by single-consortium preclinical work and a complete absence of human data after more than a decade in the literature.

Synthetic DHEA derivative / NGF mimetic

A synthetic DHEA derivative (17-spiroepoxy DHEA) developed at Bionature E.A. Ltd as a selective TrkA agonist mimicking NGF activity.

Abstract

BNN-27 (17-spiro-(2′-amino-1′,3′-thiazolin-2-yl)-androst-5-en-3-beta-ol) is a synthetic DHEA derivative developed by Bionature E.A. Ltd (Greece) and Achilleas Gravanis’s group for selective activation of TrkA, the high-affinity NGF receptor. The compound is a microneurotrophin: it mimics the NGF/TrkA pathway without binding to the p75 neurotrophin receptor (NTR). Animal studies show neuroprotective effects in models of diabetic neuropathy, retinal degeneration, and Alzheimer disease. The compound has not advanced to large clinical trials. Pharmacokinetics: oral bioavailability is good (steroid scaffold). Sold as research peptide/compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-139Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Synthetic DHEA derivative / NGF mimetic

BNN-27

Abstract

Read the full monograph